PCRX's Iovera Shows Superior Pain Relief Compared to Traditional RFA in New Clinical Trial

Pacira BioSciences (PCRX) just released pilot study data that’s turning heads in the pain management space. Their iovera system—a cutting-edge, drug-free device using cryoneurolysis technology—has outperformed radiofrequency ablation (RFA) in treating chronic low back pain (CLBP). Here’s what makes this noteworthy: the technology works by using controlled cold therapy to temporarily block pain signals at the nerve level, offering patients immediate relief that can last several months while the nerve naturally recovers.

The Clinical Data Tells a Compelling Story

The pilot enrolled 30 CLBP patients split between iovera and RFA treatment groups. What the data revealed is pretty striking:

Pain Control Outcomes:

• At the 180-day mark, iovera patients reported pain scores of 3.1 versus 5.4 for the RFA group
• By 360 days, iovera maintained its advantage at 3.0 compared to 6.1
• Functional improvements measured by Oswestry Disability Index showed iovera delivering substantially better results—10.1 at 360 days versus 20.6 for RFA

Treatment Burden: Only 45.5% of iovera-treated patients needed additional spine injections after 180 days, compared with 75% in the RFA cohort. Importantly, neither group reported treatment-related adverse events through the full 12-month follow-up.

Why This Matters for the Market

The results highlight a fundamental advantage: RFA’s heat-based mechanism can damage surrounding tissue, whereas iovera’s cold-therapy approach preserves nearby structures—particularly relevant for procedures involving sensitive areas like the interscalene block for nerve access. CLBP remains the leading cause of disability in the U.S. and fuels significant opioid consumption, with facet-mediated pain accounting for roughly 45% of cases.

Early 2025 brought another win for PCRX—FDA clearance of a new SmartTip designed for deeper nerve access during lumbar procedures, expanding iovera’s clinical potential.

The Broader PCRX Portfolio

Beyond iovera, Pacira’s pain-management arsenal includes Exparel (the flagship postsurgical analgesia product launched in 2012, also used for regional blocks) and Zilretta (an extended-release therapy for knee osteoarthritis pain). The company is actively pursuing label expansion for Zilretta into shoulder OA following a phase III study initiated in 2024.

Stock Performance & Analyst View

PCRX shares have climbed 26.1% over the past year, outpacing the broader industry’s 9.1% growth. The company currently holds a Zacks Rank #3 (Hold) rating, reflecting a “wait-and-see” posture from the analyst community as these new efficacy data circulate.